The PREVENT-COVID in Seniors Study: PRospEctiVe EvaluatioN of immuniTy after COVID-19 vaccines in Seniors
The objective of this study is to characterize and compare both short- and long-term immune responses to the different COVID-19 vaccines, including among older adults and seniors.
The specific objectives are to:
* Describe the antibody levels and function of antibodies made after vaccination with each of the four COVID-19 vaccines and compared to a younger population;
* Compare antibody quantity and function after 1 or 2 doses of different COVID-19 vaccines, particularly in priority groups;
* Define the specificity and quality of T cell responses after 1 or 2 doses of different COVID-19 vaccines;
* Understand how previous coronavirus infection (with SARS-CoV-2 and hCoVs) impacts the antibody response made to COVID-19 vaccines; and
* Determine how protective the COVID-19 vaccines are, by detecting antibodies specific for SARS-CoV-2 Nucleocapsid protein after vaccination and by linking antibody response data to SARS-CoV-2 infection status throughout the study period.
Overview
- Acronym
- PREVENT-COVID19
- Website
- PREVENT-COVID19
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2020 -
- General Information on Follow Up (profile, frequency)
-
Participants are followed-up to 9 times at regular intervals.
- Recruitment Target
-
- Individuals
- Number of Participants
- 1,000
- Number of Participants with Biological Samples
- 1,000
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Supplementary Information
Li FF, Liu A, Gibbs E, Tanunliong G, et al. A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG. Journal of Clinical Virology. 2022;146:105050. doi: 10.1016/j.jcv.2021.105050. PMID: 34883405
https://www.medrxiv.org/content/10.1101/2021.07.29.21261156v1
https://www.medrxiv.org/content/10.1101/2021.07.29.21261156v1
Timeline
Populations
PREVENT-COVID19 - BNT162b2
The population is composed of 19 years old and older individuals residing in British Columbia and who are or will be receiving the first or the second dose of BNT162b2 COVID-19 vaccine.
Selection Criteria
- Minimum age
-
19
- Countries
-
- Canada
- Canadian Provinces
-
- British Columbia
Sources of Recruitment
- General Population
-
- Volunteer enrolment
- Supplementary Information
-
Participants are recruited through the study website.
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | PREVENT-COVID19 - BNT162b2 - Baseline |
|
|
2020 (December) | Ongoing |
| 2 | PREVENT-COVID19 - BNT162b2 - Follow-up 1 |
|
|
2021 (February) | Ongoing |
| 3 | PREVENT-COVID19 - BNT162b2 - Follow-up 2 |
|
|
2021 (April) | Ongoing |
| 4 | PREVENT-COVID19 - BNT162b2 - Follow-up 3 |
|
|
2021 (June) | Ongoing |
| 5 | PREVENT-COVID19 - BNT162b2 - Follow-up 4 |
|
|
2021 (September) | Ongoing |
| 6 | PREVENT-COVID19 - BNT162b2 - Follow-up 5 |
|
|
2021 (November) | Ongoing |
| 7 | PREVENT-COVID19 - BNT162b2 - Follow-up 6 |
|
|
2022 (January) | Ongoing |
| 8 | PREVENT-COVID19 - BNT162b2 - Follow-up 7 |
|
|
2022 (March) | Ongoing |
| 8 | PREVENT-COVID19 - BNT162b2 - Follow-up 8 |
|
|
2022 (May) | Ongoing |
| 9 | PREVENT-COVID19 - BNT162b2 - Follow-up 9 |
|
|
2022 (July) | Ongoing |
PREVENT-COVID19 - mRNA-1273
The population is composed of 19 years old and older individuals residing in British Columbia and who are or will be receiving the first or the second dose of mRNA-1273 COVID-19 vaccine.
Selection Criteria
- Minimum age
-
19
- Countries
-
- Canada
- Canadian Provinces
-
- British Columbia
Sources of Recruitment
- General Population
-
- Volunteer enrolment
- Supplementary Information
-
Participants are recruited through the study website.
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | PREVENT-COVID19 - mRNA-1273 - Baseline |
|
|
2020 (December) | Ongoing |
| 1 | PREVENT-COVID19 - mRNA-1273 - Follow-up 1 |
|
|
2021 (February) | Ongoing |
| 2 | PREVENT-COVID19 - mRNA-1273 - Follow-up 2 |
|
|
2021 (April) | Ongoing |
| 3 | PREVENT-COVID19 - mRNA-1273 - Follow-up 3 |
|
|
2021 (June) | Ongoing |
| 4 | PREVENT-COVID19 - mRNA-1273 - Follow-up 4 |
|
|
2021 (September) | Ongoing |
| 5 | PREVENT-COVID19 - mRNA-1273 - Follow-up 5 |
|
|
2021 (November) | Ongoing |
| 6 | PREVENT-COVID19 - mRNA-1273 - Follow-up 6 |
|
|
2022 (January) | Ongoing |
| 7 | PREVENT-COVID19 - mRNA-1273 - Follow-up 7 |
|
|
2022 (March) | Ongoing |
| 8 | PREVENT-COVID19 - mRNA-1273 - Follow-up 8 |
|
|
2022 (May) | Ongoing |
| 9 | PREVENT-COVID19 - mRNA-1273 - Follow-up 9 |
|
|
2022 (July) | Ongoing |
PREVENT-COVID19 - ChAdOx1-S
The population is composed of 19 years old and older individuals residing in British Columbia and who are or will be receiving the first or the second dose of ChAdOx1-S COVID-19 vaccine.
Selection Criteria
- Minimum age
-
19
- Countries
-
- Canada
- Canadian Provinces
-
- British Columbia
Sources of Recruitment
- General Population
-
- Volunteer enrolment
- Supplementary Information
-
Participants are recruited through the study website.
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | PREVENT-COVID19 - ChAdOx1-S - Baseline |
|
|
2020 (December) | Ongoing |
| 1 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 1 |
|
|
2021 (February) | Ongoing |
| 2 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 2 |
|
|
2021 (April) | Ongoing |
| 3 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 3 |
|
|
2021 (June) | Ongoing |
| 4 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 4 |
|
|
2021 (September) | Ongoing |
| 5 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 5 |
|
|
2021 (November) | Ongoing |
| 6 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 6 |
|
|
2022 (January) | Ongoing |
| 7 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 7 |
|
|
2022 (March) | Ongoing |
| 8 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 8 |
|
|
2022 (May) | Ongoing |
| 9 | PREVENT-COVID19 - ChAdOx1-S - Follow-up 9 |
|
|
2022 (July) | Ongoing |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2024-02-27T15:47:58.616